Hiroshi Yoshida^1,*, Mayumi Kobayashi Kato²

Oncology Research, Vol.33, No.12, pp. 3701-3730, 2025, DOI:10.32604/or.2025.068432 - 27 November 2025

Abstract Ovarian endometrioid carcinoma (OEC) accounts for ~10% of epithelial ovarian cancers and displays broad morphologic diversity that complicates diagnosis and grading. Recent data show that the endometrial cancer molecular taxonomy (DNA polymerase epsilon, catalytic subunit [POLE]-ultramutated, mismatch repair-deficient [MMRd], p53-abnormal, no specific molecular profile [NSMP]) also applies to OEC, and that OEC is enriched for Lynch syndrome–associated tumors, supporting routine MMR testing. We aimed to synthesize contemporary evidence spanning epidemiology, histopathology and immunophenotype, diagnostic pitfalls and differential diagnosis, and to evaluate the clinical utility of The Cancer Genome Atlas (TCGA)-surrogate molecular classification for risk stratification; More >

Szymon Piątek¹, Anna Dańska-Bidzińska^2,*, Paweł Derlatka², Bartosz Szymanowski³, Renata Duchnowska³, Aleksandra Zielińska⁴, Natalia Sawicka⁴, Aleksander Gorzeń⁵, Wojciech Michalski⁶, Mariusz Bidziński¹

Oncology Research, Vol.33, No.11, pp. 3405-3416, 2025, DOI:10.32604/or.2025.068609 - 22 October 2025

Abstract Objectives: Monitoring of Cancer Antigen 125 (CA125) during ovarian cancer (OC) maintenance treatment with poly(ADP-ribose) polymerase inhibitors (PARPis) may be insufficient when using Gynecologic Cancer Intergroup (GCIG) biochemical progression criteria. This study aimed to evaluate the usefulness of CA125 monitoring in detecting OC recurrence during PARPis maintenance treatment. Methods: This multicenter retrospective cohort study included patients with primary OC who achieved complete or partial response after first-line platinum-based chemotherapy followed by PARPis maintenance treatment. Progression was defined using Response Evaluation Criteria in Solid Tumors (RECIST) and GCIG biochemical criteria. New biochemical progression definitions, based on… More >

Wenjing Liao^1,#, Liaodi Wang^2,#, Zhen Huang¹, Ziyu Zou¹, Yimin Liu¹, Haoyue Liu¹, Zhaoning Duan¹, Liangdan Tang^1,*

Oncology Research, Vol.33, No.10, pp. 3041-3064, 2025, DOI:10.32604/or.2025.065451 - 26 September 2025

Abstract Objectives: Ovarian cancer (OC) is a highly heterogeneous disease characterized by high metastatic potential and frequent recurrence. 3β-hydroxysterol Δ24-reductase (DHCR24) is closely associated with the progression of various malignant tumors, but its role in OC remains unexplored. This study is the first to systematically investigate the function of DHCR24 in OC and elucidate its mechanism in promoting OC progression, providing novel theoretical insights for targeted therapy. Methods: The expression of DHCR24 was evaluated in tissues using bioinformatics and clinical data; the impact of DHCR24 on the malignant behavior of OC was assessed through in vivo and in… More >

Liang Yu^1,#, Mingrui Zhao^1,#, Jinhui Liu², Yuqin Yang¹, Lin Zhang², Wenjun Cheng^2,*

Oncology Research, Vol.33, No.10, pp. 3007-3022, 2025, DOI:10.32604/or.2025.065137 - 26 September 2025

Abstract Background: The benefit of adjuvant chemotherapy for stage I ovarian endometrioid carcinoma (OEC) remains controversial. Hence, the study sought to explore its value in stage I OEC patients. Methods: Stage I OEC patients (1988–2018) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox analysis was used to control confounders. Logistic regression was used to explore factors associated with adjuvant chemotherapy. Cox regression analysis and Kaplan-Meier curves were used to assess the survival benefits. Single-center clinical data and meta-analysis following PRISMA guidelines provided external validation. Result: Adjuvant chemotherapy correlated with improved survival (Hazard… More >

Lingjuan Linghu^1,#, Hongying Zhou^2,#, Gang Zheng¹, Tao Yi^1,*

Oncology Research, Vol.33, No.9, pp. 2421-2434, 2025, DOI:10.32604/or.2025.063724 - 28 August 2025

Abstract Objectives: Ovarian cancer, a leading cause of gynecological malignancy-related mortality, is characterized by limited therapeutic options and a poor prognosis. Although pyrimethamine has emerged as a promising candidate demonstrating efficacy in treating various tumors, the precise mechanisms of its antitumor effects remain obscure. This study was specifically designed to investigate the mode of action underlying the antitumor effects of pyrimethamine in preclinical settings. Methods: The effects of pyrimethamine on cellular proliferation were meticulously assessed using both the cell counting kit 8 (CCK-8) assay and the colony formation assay, with the effects further confirmed in a… More >

Yuhan Wang, Yimei Meng, Wanqiu Xia, Yusen Liang, Yaru Wang, Peiling Li^*, Lei Fang^*

Oncology Research, Vol.33, No.8, pp. 2141-2159, 2025, DOI:10.32604/or.2025.064367 - 18 July 2025

Abstract Background: Ovarian cancer (OC) is a representative malignancy of the female reproductive system, with a poor prognosis. Long non-coding RNAs (lncRNAs) crucially affect tumor development. This study aimed to identify lncRNAs that potentially participated in OC. Methods: LncRNA expression in cells and tissues was quantified using reverse transcription-quantitative PCR, while fluorescence in situ hybridization determined their cellular localization. Various in vitro assays, together with a mouse xenograft model, were employed to elucidate the function of CYMP antisense RNA 1 (CYMP-AS1) in OC. The molecular mechanisms underlying CYMP-AS1 regulation were investigated through RNA pull-down and immunoprecipitation assays, immunofluorescence… More > Graphic Abstract

Oncology Research Editorial Office

Oncology Research, Vol.33, No.7, pp. 1801-1802, 2025, DOI:10.32604/or.2025.068988 - 26 June 2025

Abstract This article has no abstract. More >

RAZIEH MOMEN-MESGIN¹, JAFAR REZAIE^2,*, VAHID NEJATI¹, PEYMAN NAJAFI MOGHADAM³

Oncology Research, Vol.33, No.3, pp. 665-674, 2025, DOI:10.32604/or.2024.054487 - 28 February 2025

Abstract Objectives: Due to systematic side effects, there is a growing interest in nanoparticle formulation of anticancer drugs. Here, we aimed to synthesize poly (styrene-alt-maleic anhydride) cross-linked by melamine (PSMA/Me) and coated with magnetite nanoparticles (MNPs) PSMA/Me/Fe₃O₄. In addition, we aimed to load paclitaxel (PTX) into PSMA/Me/Fe₃O₄ for drug delivery and anticancer investigations. Methods: Novel PSMA/Me was synthesized via free radical copolymerization, coated with Fe₃O₄, and then used as a transporter for PTX delivery. Fabricated copolymer was characterized using SEM, TGA, and XRD techniques. Drug release rate and loading efficiency were investigated. Human ovarian cancer cells (Skov-3) and… More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.10, pp. 1689-1690, 2024, DOI:10.32604/or.2024.056905 - 18 September 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.9, pp. 1541-1541, 2024, DOI:10.32604/or.2024.056127 - 23 August 2024

Abstract This article has no abstract. More >